Skip to main content
Top
Published in:

05-10-2024 | Gastroesophageal Reflux Disease

Emerging Diagnostic Tools and Medical Management of GERD

Authors: Eliza Cricco-Lizza, Philip O. Katz

Published in: Current Treatment Options in Gastroenterology | Issue 4/2024

Login to get access

Abstract

Purpose of Review

Gastroesophageal reflux disease (GERD) remains one of the most common conditions seen by gastroenterologists, with variable practices regarding diagnostic workup, empiric treatment, and type and duration of medical management.
There are multiple new advancements in the multimodal approach to behavioral and lifestyle management as well as novel medications that will likely change the current paradigm.
The purpose of this review is to discuss these emerging medical and interventional treatment options, provide the latest evidence-based data and personal insights into current practices.
This summary will address GERD. We will not specifically address disorders of gut brain interaction, and other esophageal pathologies such as eosinophilic esophagitis and achalasia.

Recent Findings

Increased evidence and expert consensus have emerged related to procedural intervention for patients not responding to proton-pump inhibitors (PPI), with updated recommendations regarding laparoscopic fundoplication for those with a large hiatal hernia, magnetic sphincter augmentation for regurgitation-predominant symptoms, and transoral incisionless fundoplication in selected patients with mild GERD and a small hiatal hernia. Potassium-Competitive Acid Blockers (PCABs) are now available. Recent data demonstrate potential advantages compared to PPIs and will clearly augment our options for medical treatment of GERD patients.

Summary

We provide updated treatment options for the management of GERD, highlighting the most recent advancements in approaching minimally invasive procedural interventions, which patients are best suited for these procedures, insight on appropriate medication use, and discussion of the role of the recently approved PCAB medication.
Literature
1.
go back to reference Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022;117(1):27–56.CrossRefPubMedPubMedCentral Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022;117(1):27–56.CrossRefPubMedPubMedCentral
2.
go back to reference Yadlapati R, Gyawali CP, Pandolfino JE, CGIT GERD Consensus Conference Participants. AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review. Clin Gastroenterol Hepatol. 2022;20(5):984-9941.e1.CrossRefPubMedPubMedCentral Yadlapati R, Gyawali CP, Pandolfino JE, CGIT GERD Consensus Conference Participants. AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review. Clin Gastroenterol Hepatol. 2022;20(5):984-9941.e1.CrossRefPubMedPubMedCentral
3.
go back to reference Newberry C, Lynch K. Lifestyle Management of Gastroesophageal Reflux Disease: Evidence-Based Approaches to Improve Patient Care. Foregut: J Am Foregut Soc. 2021;1(2):139–44.CrossRef Newberry C, Lynch K. Lifestyle Management of Gastroesophageal Reflux Disease: Evidence-Based Approaches to Improve Patient Care. Foregut: J Am Foregut Soc. 2021;1(2):139–44.CrossRef
4.
go back to reference Zdrhova L, Bitnar P, Balihar K, Kolar P, Madle K, Martinek M, et al. Breathing Exercises in Gastroesophageal Reflux Disease: A Systematic Review. Dysphagia. 2023;38(2):609–21.CrossRefPubMed Zdrhova L, Bitnar P, Balihar K, Kolar P, Madle K, Martinek M, et al. Breathing Exercises in Gastroesophageal Reflux Disease: A Systematic Review. Dysphagia. 2023;38(2):609–21.CrossRefPubMed
5.
go back to reference Bor S, Kalkan İH, Çelebi A, Dinçer D, Akyüz F, Dettmar P, et al. Alginates: From the ocean to gastroesophageal reflux disease treatment. Turk J Gastroenterol. 2019;30(Suppl 2):S109–36.CrossRefPubMedCentral Bor S, Kalkan İH, Çelebi A, Dinçer D, Akyüz F, Dettmar P, et al. Alginates: From the ocean to gastroesophageal reflux disease treatment. Turk J Gastroenterol. 2019;30(Suppl 2):S109–36.CrossRefPubMedCentral
6.
go back to reference Laine L, DeVault K, Katz P, Mitev S, Lowe J, Hunt B, et al. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial. Gastroenterology. 2023;164(1):61–71.CrossRefPubMed Laine L, DeVault K, Katz P, Mitev S, Lowe J, Hunt B, et al. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial. Gastroenterology. 2023;164(1):61–71.CrossRefPubMed
7.
go back to reference Wong N, Reddy A, Patel A. Potassium-Competitive Acid Blockers: Present and Potential Utility in the Armamentarium for Acid Peptic Disorders. Gastroenterol Hepatol (N Y). 2022;18(12):693–700.PubMed Wong N, Reddy A, Patel A. Potassium-Competitive Acid Blockers: Present and Potential Utility in the Armamentarium for Acid Peptic Disorders. Gastroenterol Hepatol (N Y). 2022;18(12):693–700.PubMed
8.
go back to reference Sloan JA, Katz PO. Proton Pump Inhibitors in 2021: Pros, Cons, and Everything in Between. Foregut. 2021;1(2):145–51.CrossRef Sloan JA, Katz PO. Proton Pump Inhibitors in 2021: Pros, Cons, and Everything in Between. Foregut. 2021;1(2):145–51.CrossRef
9.
go back to reference Yibirin M, De Oliveira D, Valera R, Plitt AE, Lutgen S. Adverse Effects Associated with Proton Pump Inhibitor Use. Cureus. 2021;13(1):e12759.PubMedPubMedCentral Yibirin M, De Oliveira D, Valera R, Plitt AE, Lutgen S. Adverse Effects Associated with Proton Pump Inhibitor Use. Cureus. 2021;13(1):e12759.PubMedPubMedCentral
10.
go back to reference Jamshed S, Bhagavathula AS, Zeeshan Qadar SM, Alauddin U, Shamim S, Hasan S. Cost-effective Analysis of Proton Pump Inhibitors in Long-term Management of Gastroesophageal Reflux Disease: A Narrative Review. Hosp Pharm. 2020;55(5):292–305.CrossRefPubMed Jamshed S, Bhagavathula AS, Zeeshan Qadar SM, Alauddin U, Shamim S, Hasan S. Cost-effective Analysis of Proton Pump Inhibitors in Long-term Management of Gastroesophageal Reflux Disease: A Narrative Review. Hosp Pharm. 2020;55(5):292–305.CrossRefPubMed
11.
go back to reference Arabpour E, Khoshdel S, Akhgarzad A, Abdi M, Tabatabaie N, Alijanzadeh D, et al. Baclofen as a therapeutic option for gastroesophageal reflux disease: A systematic review of clinical trials. Front Med [Internet]. 2023 Feb 17 [cited 2024 Mar 27];10. Available from: https://www.frontiersin.org/articles/https://doi.org/10.3389/fmed.2023.997440 Arabpour E, Khoshdel S, Akhgarzad A, Abdi M, Tabatabaie N, Alijanzadeh D, et al. Baclofen as a therapeutic option for gastroesophageal reflux disease: A systematic review of clinical trials. Front Med [Internet]. 2023 Feb 17 [cited 2024 Mar 27];10. Available from: https://​www.​frontiersin.​org/​articles/​https://​doi.​org/​10.​3389/​fmed.​2023.​997440
12.
go back to reference Wilkinson J, Wade A, Thomas SJ, Jenner B, Hodgkinson V, Coyle C. Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate–antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2019;31(1):86–93.CrossRefPubMed Wilkinson J, Wade A, Thomas SJ, Jenner B, Hodgkinson V, Coyle C. Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate–antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2019;31(1):86–93.CrossRefPubMed
13.
go back to reference Zhao CX, Wang JW, Gong M. Efficacy and safety of alginate formulations in patients with gastroesophageal reflux disease: a systematic review and meta-analysis of randomized controlled trials. Eur Rev Med Pharmacol Sci. 2020;24(22):11845–57.PubMed Zhao CX, Wang JW, Gong M. Efficacy and safety of alginate formulations in patients with gastroesophageal reflux disease: a systematic review and meta-analysis of randomized controlled trials. Eur Rev Med Pharmacol Sci. 2020;24(22):11845–57.PubMed
14.
go back to reference Ng VV, Booth MI, Stratford JJ, Jones L, Sohanpal J, Dehn TC. Laparoscopic Anti-Reflux Surgery is Effective in Obese Patients with Gastro-Oesophageal Reflux Disease. Ann R Coll Surg Engl. 2007;89(7):696.CrossRefPubMedPubMedCentral Ng VV, Booth MI, Stratford JJ, Jones L, Sohanpal J, Dehn TC. Laparoscopic Anti-Reflux Surgery is Effective in Obese Patients with Gastro-Oesophageal Reflux Disease. Ann R Coll Surg Engl. 2007;89(7):696.CrossRefPubMedPubMedCentral
15.
go back to reference Abdelrahman T, Latif A, Chan DS, Jones H, Farag M, Lewis WG, et al. Outcomes after laparoscopic anti-reflux surgery related to obesity: A systematic review and meta-analysis. Int J Surg. 2018;51:76–82.CrossRefPubMed Abdelrahman T, Latif A, Chan DS, Jones H, Farag M, Lewis WG, et al. Outcomes after laparoscopic anti-reflux surgery related to obesity: A systematic review and meta-analysis. Int J Surg. 2018;51:76–82.CrossRefPubMed
16.
go back to reference Greenberg JA, Palacardo F, Edelmuth RCL, Egan CE, Lee YJ, Schnoll-Sussman FH, et al. Comparative Outcomes of Anti-Reflux Surgery in Obese Patients with Gastroesophageal Reflux Disease1. J Gastrointest Surg. 2023;27(3):502–10.CrossRefPubMed Greenberg JA, Palacardo F, Edelmuth RCL, Egan CE, Lee YJ, Schnoll-Sussman FH, et al. Comparative Outcomes of Anti-Reflux Surgery in Obese Patients with Gastroesophageal Reflux Disease1. J Gastrointest Surg. 2023;27(3):502–10.CrossRefPubMed
17.
go back to reference Shah A, Kim MP. Gastroesophageal Reflux Disease in 2023: When to Operate and Current Endoscopic Options for Antireflux Therapy. Thorac Surg Clin. 2023;33(2):125–34.CrossRefPubMed Shah A, Kim MP. Gastroesophageal Reflux Disease in 2023: When to Operate and Current Endoscopic Options for Antireflux Therapy. Thorac Surg Clin. 2023;33(2):125–34.CrossRefPubMed
18.
go back to reference Ramai D, Shapiro A, Barakat M, Facciorusso A, Dull A, Chandan S, et al. Adverse events associated with transoral incisionless fundoplication (TIF) for chronic gastroesophageal reflux disease: a MAUDE database analysis. Surg Endosc. 2022;36(7):4956–9.CrossRefPubMed Ramai D, Shapiro A, Barakat M, Facciorusso A, Dull A, Chandan S, et al. Adverse events associated with transoral incisionless fundoplication (TIF) for chronic gastroesophageal reflux disease: a MAUDE database analysis. Surg Endosc. 2022;36(7):4956–9.CrossRefPubMed
19.
go back to reference McCarty TR, Jirapinyo P, James LP, Gupta S, Chan WW, Thompson CC. Transoral incisionless fundoplication is cost-effective for treatment of gastroesophageal reflux disease. Endosc Int Open. 2022;10(7):E923–32.CrossRefPubMedPubMedCentral McCarty TR, Jirapinyo P, James LP, Gupta S, Chan WW, Thompson CC. Transoral incisionless fundoplication is cost-effective for treatment of gastroesophageal reflux disease. Endosc Int Open. 2022;10(7):E923–32.CrossRefPubMedPubMedCentral
20.
go back to reference Slater BJ, Collings A, Dirks R, Gould JC, Qureshi AP, Juza R, et al. Multi-society consensus conference and guideline on the treatment of gastroesophageal reflux disease (GERD). Surg Endosc. 2023;37(2):781–806.CrossRefPubMed Slater BJ, Collings A, Dirks R, Gould JC, Qureshi AP, Juza R, et al. Multi-society consensus conference and guideline on the treatment of gastroesophageal reflux disease (GERD). Surg Endosc. 2023;37(2):781–806.CrossRefPubMed
21.
go back to reference Comay D, Adam V, Silveira E, Kennedy W, Mayrand S, Barkun A. The Stretta Procedure Versus Proton Pump Inhibitors and Laparoscopic Nissen Fundoplication in the Management of Gastroesophageal Reflux Disease: A Cost-Effectiveness Analysis. Canadian Journal of Gastroenterology = Journal Canadien de Gastroenterologie. 2008; 1;22:552–8 Comay D, Adam V, Silveira E, Kennedy W, Mayrand S, Barkun A. The Stretta Procedure Versus Proton Pump Inhibitors and Laparoscopic Nissen Fundoplication in the Management of Gastroesophageal Reflux Disease: A Cost-Effectiveness Analysis. Canadian Journal of Gastroenterology = Journal Canadien de Gastroenterologie. 2008; 1;22:552–8
22.
go back to reference Richter JE. Gastroesophageal reflux disease treatment: side effects and complications of fundoplication. Clin Gastroenterol Hepatol. 2013;11(5):465–71; quiz e39 Richter JE. Gastroesophageal reflux disease treatment: side effects and complications of fundoplication. Clin Gastroenterol Hepatol. 2013;11(5):465–71; quiz e39
23.
go back to reference Shehryar M, Ahmad RU, Kareem HK, Khan L, Ashraf MF, Hassan A, et al. (2022) Efficacy, safety and cost-effectiveness of vonoprazan vs Proton Pump Inhibitors in reflux disorders and H. pylori eradication: A literature review. Ann Med Surg (Lond). 22;82:104760 Shehryar M, Ahmad RU, Kareem HK, Khan L, Ashraf MF, Hassan A, et al. (2022) Efficacy, safety and cost-effectiveness of vonoprazan vs Proton Pump Inhibitors in reflux disorders and H. pylori eradication: A literature review. Ann Med Surg (Lond). 22;82:104760
Metadata
Title
Emerging Diagnostic Tools and Medical Management of GERD
Authors
Eliza Cricco-Lizza
Philip O. Katz
Publication date
05-10-2024